The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD).
For this study, all subjects will receive Restasis (Cyclosporine ophthalmic emulsion 0.05%). One drop of the dispensed study drop will be instilled in the PROSE lens reservoir twice a day and the remainder of the reservoir will be filled with normal saline (0.9% sodium chloride solution). In order to standardize solutions used in the PROSE reservoir, all patients recruited will be either currently using or will be switched to buffered preservative-free normal saline (Purilens, Lifestyle Inc., pH 7.4 ) to better match the reported pH of RESTASIS (pH 6.5-8.05).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
All subjects will receive restasis
BostonSight
Needham, Massachusetts, United States
subjective responses regarding symptoms
Subjects will be given a baseline tolerability questionnaire Disease Index (OSDI)
Time frame: Baseline
subjective responses regarding symptoms
Subjects will be given a baseline tolerability questionnaire Disease Index (OSDI)
Time frame: 1 week
subjective responses regarding symptoms
Subjects will be given a baseline tolerability questionnaire Disease Index (OSDI)
Time frame: 1 month
Oculus keratograph scan
A scan of the eye surface will classify eye redness
Time frame: Baseline
Oculus keratograph scan
A scan of the eye surface will classify eye redness
Time frame: 1 week
Oculus keratograph scan
A scan of the eye surface will classify eye redness
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.